Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
AVBP
Stock Latest News
Ratings
ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
9h ago
AVBP
Premium
The Fly
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
20d ago
AVBP
Premium
The Fly
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study
21d ago
AVBP
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
1M ago
AMZN
APGE
Premium
The Fly
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential
1M ago
AVBP
Premium
The Fly
ArriVent Biopharma initiated with a Buy at BTIG
1M ago
AVBP
Premium
Ratings
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment
1M ago
AVBP
Premium
Ratings
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results
1M ago
AVBP
Premium
The Fly
ArriVent Biopharma initiated with a Buy at Truist
2M ago
AVBP
Premium
Ratings
ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target
2M ago
AVBP
Premium
The Fly
ArriVent Biopharma management to meet virtually with Clear Street
2M ago
AVBP
Premium
The Fly
ArriVent Biopharma price target lowered to $31 from $33 at Citi
2M ago
AVBP
Premium
Company Announcements
ArriVent BioPharma Reports Q3 2025 Financial Results
2M ago
AVBP
Premium
Ratings
ArriVent BioPharma’s Promising Trial Results and Strategic Developments Drive Buy Rating
2M ago
AVBP
Premium
The Fly
ArriVent Biopharma reports Q3 EPS (83c), consensus (78c)
2M ago
AVBP
Premium
The Fly
ArriVent Biopharma price target raised to $47 from $32 at Clear Street
2M ago
AVBP
Premium
Company Announcements
ArriVent BioPharma’s Phase 3 Study on Firmonertinib: A Potential Game-Changer in NSCLC Treatment
3M ago
AVBP
Premium
Company Announcements
ArriVent BioPharma’s Phase 3 Study on Firmonertinib: A Potential Game-Changer in NSCLC Treatment
3M ago
AVBP
Premium
The Fly
ArriVent Biopharma appoints Brent Rice as chief commercial officer
4M ago
AUTL
AVBP
Premium
Market News
3 Best Stocks to Buy Now, 9/10/2025, According to Top Analysts
4M ago
AVBP
NVDA
Premium
Ratings
ArriVent BioPharma Buy Rating: Strong Clinical Data and Strategic Positioning Highlight Potential
4M ago
AVBP
Premium
Ratings
Promising Market Position and Strong Clinical Results Lead to Buy Rating for ArriVent BioPharma, Inc.
4M ago
AVBP
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
